Nuvation Bio Management
Management criteria checks 2/4
Nuvation Bio's CEO is David Hung, appointed in Apr 2018, has a tenure of 6.58 years. total yearly compensation is $4.32M, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 17.61% of the company’s shares, worth $152.95M. The average tenure of the management team and the board of directors is 2.3 years and 1.4 years respectively.
Key information
David Hung
Chief executive officer
US$4.3m
Total compensation
| CEO salary percentage | 13.7% |
| CEO tenure | 6.6yrs |
| CEO ownership | 17.6% |
| Management average tenure | 2.3yrs |
| Board average tenure | 1.4yrs |
Recent management updates
Recent updates
Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Nov 20
Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Oct 21Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Aug 08Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Aug 07Nuvation Bio: A Potentially Transformative Acquisition
Jun 20Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$532m |
| Jun 30 2024 | n/a | n/a | -US$511m |
| Mar 31 2024 | n/a | n/a | -US$69m |
| Dec 31 2023 | US$4m | US$593k | -US$76m |
| Sep 30 2023 | n/a | n/a | -US$83m |
| Jun 30 2023 | n/a | n/a | -US$90m |
| Mar 31 2023 | n/a | n/a | -US$105m |
| Dec 31 2022 | US$8m | US$570k | -US$104m |
| Sep 30 2022 | n/a | n/a | -US$108m |
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$88m |
| Dec 31 2021 | US$5m | US$550k | -US$87m |
| Sep 30 2021 | n/a | n/a | -US$75m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$1m | US$475k | -US$42m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$32m |
| Mar 31 2020 | n/a | n/a | -US$33m |
| Dec 31 2019 | US$364k | US$218k | -US$34m |
Compensation vs Market: David's total compensation ($USD4.32M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Hung (66 yo)
6.6yrs
Tenure
US$4,324,280
Compensation
Dr. David T. Hung, M.D., serves as Founder, President, Chief Executive Officer and Director at Nuvation Bio Inc since April 2018 and has been it's Chairman of the Board since September 03, 2024. He founded...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.6yrs | US$4.32m | 17.61% $ 152.9m | |
| Chief Scientific Officer | 5.4yrs | US$1.36m | 0% $ 0 | |
| Chief Medical Officer | 2.3yrs | US$1.34m | 0.0027% $ 23.2k | |
| Chief Financial Officer & Principal Financial Officer | less than a year | no data | no data | |
| VP of Finance and Principal Accounting & Financial Officer | less than a year | no data | 0.0032% $ 27.4k | |
| VP of Legal & Secretary | no data | no data | no data | |
| Chief People Officer | 5.1yrs | no data | 0.0032% $ 27.4k | |
| Chief Technical Operations Officer | 3.4yrs | US$3.31m | 0.0036% $ 31.0k | |
| Chief Regulatory Officer | 2.3yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | 0.0074% $ 64.5k | |
| CEO & Co-Founder of AnHeart Therapeutics and Director | less than a year | no data | 1.82% $ 15.8m |
2.3yrs
Average Tenure
54yo
Average Age
Experienced Management: NUVB's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.6yrs | US$4.32m | 17.61% $ 152.9m | |
| CEO & Co-Founder of AnHeart Therapeutics and Director | less than a year | no data | 1.82% $ 15.8m | |
| Independent Director | 4.1yrs | US$447.77k | 0.074% $ 645.0k | |
| Independent Director | 5.3yrs | US$440.35k | 0.051% $ 444.2k | |
| Member of Scientific Advisory Board | 1.4yrs | no data | no data | |
| Independent Director | 5.4yrs | US$448.68k | 0.090% $ 784.5k | |
| Member of Scientific Advisory Board | 1.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.4yrs | no data | no data | |
| Lead Independent Director | 4.3yrs | US$442.60k | no data | |
| Member of Scientific Advisory Board | 1.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.4yrs | no data | no data |
1.4yrs
Average Tenure
63yo
Average Age
Experienced Board: NUVB's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.